Literature DB >> 18246523

Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.

Daniel Parish1, Noah Scheinfeld.   

Abstract

Forest Laboratories (following its acquisition of Cerexa Inc, a spin-out from Peninsula Pharmaceuticals Inc), under license from Takeda, is developing ceftaroline fosamil, an N-phosphono prodrug of ceftaroline, a derivative of a fourth-generation cephalosporin, for the potential treatment of methicillin-resistant Staphylococcus aureus infection. Phase III clinical trials evaluating ceftaroline fosamil for community acquired pneumonia and complicated skin and skin structure infections are underway.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18246523

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  13 in total

1.  PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  S Wesley Long; Randall J Olsen; Shrenik C Mehta; Timothy Palzkill; Patricia L Cernoch; Katherine K Perez; William L Musick; Adriana E Rosato; James M Musser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 3.  Community-associated meticillin-resistant Staphylococcus aureus.

Authors:  Frank R DeLeo; Michael Otto; Barry N Kreiswirth; Henry F Chambers
Journal:  Lancet       Date:  2010-03-05       Impact factor: 79.321

4.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

5.  Postantibiotic effect of ceftaroline against gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

Review 6.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Céline Vidaillac; Steve N Leonard; Helio S Sader; Ronald N Jones; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

8.  In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Authors:  Céline Vidaillac; Steve N Leonard; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 9.  Waves of resistance: Staphylococcus aureus in the antibiotic era.

Authors:  Henry F Chambers; Frank R Deleo
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633

10.  In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.

Authors:  D M Citron; K L Tyrrell; C V Merriam; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.